Piperidine and azetidine derivatives as GlyT1 inhibitors

Details Piperidine and azetidine derivatives as GlyT1 inhibitors Piperidine and azetidine derivatives as GlyT1 inhibitors

2005-12-21

2010-02-02

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S318000, C514S326000

Reexamination Certificate

active

07655644

ABSTRACT:
The present invention provides compounds of formula (I), wherein both p's are one or two, R1is generally heteroaryl or cycloalkyl, R2is C3-6cycloalkyl or phenyl and R3is heteroaryl, and pharmaceutically acceptable salts thereof, as GlyT1 inhibitors for treating schizophrenia, pharmaceutical compositions comprising the same and methods for their preparation.

REFERENCES:
patent: 2005/0272751 (2005-12-01), McKerracher et al.
patent: 2006/0276655 (2006-12-01), Blackaby et al.
patent: 2007/0105902 (2007-05-01), Lindsley et al.
patent: 2007/0249606 (2007-10-01), Lindsley et al.
patent: 2007/0254880 (2007-11-01), Blackaby et al.
patent: 2008/0021010 (2008-01-01), Lindsley et al.
patent: 2008/0090796 (2008-04-01), Blackaby et al.
patent: WO 99/52519 (1999-10-01), None
patent: WO 03/088908 (2003-10-01), None
patent: WO 2005/094514 (2005-10-01), None
Copending U.S. Appl. No. 11/922,074, filed Jun. 13, 2006, U.S. National Stage Entry of PCT/GB06/002156, published as WO 2006/134341.
Copending U.S. Appl. No. 11/991,727, filed Sep. 25, 2006, U.S. National Stage Entry of PCT/GB06/036989, published as WO 2007/041025.
Copending U.S. Appl. No. 12/084,027, filed Oct. 27, 2006, U.S. National Stage Entry of PCT/GB06/041699, published as WO 2007/053400.
Copending U.S. Appl. No. 12/085,340, filed Nov. 23, 2006, U.S. National Stage Entry of PCT/GB06/050411, published as WO 2007/060484.

Affiliated with

Also associated with

Rating

Piperidine and azetidine derivatives as GlyT1 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperidine and azetidine derivatives as GlyT1 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine and azetidine derivatives as GlyT1 inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4232011